Company intelligence / Profile preview

Speratum Biopharma

Dover, Delaware, United Statessperatum.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lead candidate NM‑198 has demonstrated potent tumor-suppressive effects across multiple solid tumor models preclinically. The company holds patents covering use of miR‑198 against several cancers. IND-enabling studies are ongoing; no clinical results yet reported.

Therapeutic areas: Oncology
Modalities: microRNA (miRNA)-based therapeutics (notably miR-198 mimics)Oligonucleotides (including siRNA and antisense oligonucleotides)mRNA-based medicinesGene editing solutions
Industry: Biotech

Drug pipeline

2 assets

NM-198

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Speratum Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Speratum Biopharma.

Explore the full profile